 |
|
Safety of an Intravitreal Injection of Triamcinolone
Results From a Randomized Clinical Trial
Mark C. Gillies, MD, PhD;
Judy M. Simpson, PhD;
Frank A. Billson, MD;
Wei Luo, MD, MPH;
Philip Penfold, PhD;
William Chua, MD;
Paul Mitchell, MD, PhD;
Meidong Zhu, MD, PhD;
Alex B. L. Hunyor, MD
Arch Ophthalmol. 2004;122:336-340.
Objective To determine the safety of a single intravitreal injection of triamcinolone acetonide (4 mg) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration.
Methods A double-masked, placebo-controlled, randomized clinical trial was conducted at a public tertiary referral eye hospital. Patients participating had age-related macular degeneration with evidence of choroidal neovascularization, any part of which was classic; age older than 59 years; and best-corrected visual acuity of 20/200 or better. Eyes were assigned to active study treatment or to placebo. Intraocular pressure and cataract grading were performed every 6 months for 3 years. Adverse events, from mild to vision-threatening or life-threatening, were recorded as procedure-related or corticosteroid-related.
Results Seventy-five eyes were assigned to study treatment and 76 eyes to placebo. There were no moderate or severe adverse events related to the surgical procedure in either group. Triamcinolone-treated eyes had a significantly increased risk of developing mild or moderate elevation of the intraocular pressure. Topical glaucoma medication reduced intraocular pressure to acceptable levels in all patients. There was significant progression of cataract in the triamcinolone-treated eyes.
Conclusion Despite a significant adverse event profile, intravitreal triamcinolone is generally well tolerated by the human eye as long as patients are carefully followed up by their surgeon and treated appropriately, when necessary.
From the Save Sight and Eye Health Institute, Department of Clinical Ophthalmology (Drs Gillies, Billson, Luo, Penfold, Chua, Mitchell and Zhu), School of Public Health (Dr Simpson), and Sydney Eye Hospital (Dr Hunyor), University of Sydney, Sydney, New South Wales, Australia. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections
Tammewar et al.
Br. J. Ophthalmol. 2008;92:810-813.
ABSTRACT
| FULL TEXT
Short-term Safety and Efficacy of Intravitreal Triamcinolone Acetonide for Uveitic Macular Edema in Children
Sallam et al.
Arch Ophthalmol 2008;126:200-205.
ABSTRACT
| FULL TEXT
Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema
Gillies et al.
Br. J. Ophthalmol. 2007;91:1323-1326.
ABSTRACT
| FULL TEXT
Effects of intravitreal triamcinolone acetonide injection with and without preservative
Maia et al.
Br. J. Ophthalmol. 2007;91:1122-1124.
ABSTRACT
| FULL TEXT
Management of Diabetic Retinopathy: A Systematic Review
Mohamed et al.
JAMA 2007;298:902-916.
ABSTRACT
| FULL TEXT
Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study
Brasil et al.
Br. J. Ophthalmol. 2007;91:761-765.
ABSTRACT
| FULL TEXT
Intraocular pressure alterations following intravitreal triamcinolone acetonide
Rhee et al.
Br. J. Ophthalmol. 2006;90:999-1003.
ABSTRACT
| FULL TEXT
A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT
Perspectives on verteporfin therapy combined with intravitreal corticosteroids.
Schmidt-Erfurth et al.
Arch Ophthalmol 2006;124:561-563.
FULL TEXT
Should corticosteroids be considered as part of the standard care with photodynamic therapy?
Zarbin
Arch Ophthalmol 2006;124:563-571.
FULL TEXT
Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.
Chan et al.
Br. J. Ophthalmol. 2006;90:337-341.
ABSTRACT
| FULL TEXT
Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema
Spandau et al.
Br. J. Ophthalmol. 2005;89:999-1003.
ABSTRACT
| FULL TEXT
Intravitreal triamcinolone therapy for diabetic macular oedema
Vernon
Br. J. Ophthalmol. 2005;89:931-933.
FULL TEXT
|
